Details for New Drug Application (NDA): 018152
✉ Email this page to a colleague
NDA 018152 describes ESKALITH CR, which is a drug marketed by Jds Pharms and is included in one NDA. Additional details are available on the ESKALITH CR profile page.
The generic ingredient in ESKALITH CR is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
The generic ingredient in ESKALITH CR is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 018152
| Tradename: | ESKALITH CR |
| Applicant: | Jds Pharms |
| Ingredient: | lithium carbonate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 018152
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 450MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 29, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
